Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

ImmuPharma (25I) Stock Price & Analysis

25I Stock Chart & Stats

€0.02-€0.01(-26.92%)
At close: 5:30 PM GMT+1
EUR 0.045EUR 0.05EUR 0.055EUR 0.0620 Aug31 Aug21 Sep30 Sep
Day’s Range
EUR 0.02 - EUR 0.03
52-Week Range
EUR 0.02 - EUR 0.12
Previous Close
EUR 0.03
Volume
0
Average Volume (3M)
2,576
Market Cap
EUR 24.24M
Enterprise Value
EUR 20.22M
Total Cash (Recent Filing)
EUR 695.84K
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
6.97
Next Earnings
May 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Financial Leverage

Debt at or near zero reduces default and interest-burden risk, preserving financial flexibility while the company advances its drug candidates. This gives management more room to allocate capital toward development and potentially pursue partnerships without a large existing debt load.

Improved Equity Position

The return to positive equity provides a stronger capital base than in 2024 and partially offsets the company’s weak earnings profile. Although it does not indicate profitability, the improvement may support continued operations and reduce balance-sheet stress over the next several months.

Growing Asset Base

An expanded asset base indicates that the company retains a larger pool of resources supporting its ongoing operations and development activities than previously. This is a constructive balance-sheet trend, although its lasting value depends on whether the assets can ultimately support commercial or partnered returns.

Bears Say

Minimal Revenue Base

The absence of a meaningful revenue base leaves ImmuPharma dependent on future clinical progress, licensing transactions, or external financing rather than recurring operating income. This makes financial performance highly dependent on successful development and commercialization outcomes.

Widening Losses

Losses have widened substantially, showing that current research and overhead spending is not yet supported by revenue. Persistent negative EBIT and EBITDA increase the amount of capital required to sustain development and make near-term profitability less dependable.

Persistent Cash Burn

Sustained negative operating and free cash flow means the business is not currently funding itself through operations. Continued cash burn creates an ongoing need for external funding, which can constrain development plans and increase financing dependence over the next several quarters.

ImmuPharma News

25I FAQ

What was ImmuPharma’s price range in the past 12 months?
ImmuPharma lowest stock price was €0.02 and its highest was €0.12 in the past 12 months.
What is ImmuPharma’s market cap?
ImmuPharma’s market cap is €24.24M.
When is ImmuPharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImmuPharma’s earnings last quarter?
ImmuPharma released its earnings results on Sep 15, 2026. The company reported -€0.009 earnings per share for the quarter.
Is ImmuPharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does ImmuPharma pay dividends?
ImmuPharma does not currently pay dividends.
What is ImmuPharma’s EPS estimate?
ImmuPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma have?
ImmuPharma has 623,911,400 shares outstanding.
What happened to ImmuPharma’s price movement after its last earnings report?
ImmuPharma reported an EPS of -€0.009 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ImmuPharma?
Currently, no hedge funds are holding shares in DE:25I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology